# PROJECT_STATE_CONTINUATION

## Current Project State

Repo: `fyz1500wr/pharma-analytical-method-lifecycle-platform`

Project status: **Phase 2 technical foundation implemented; SME review pending**

This project has been initiated as the main repository for the **Pharmaceutical Analytical Method Lifecycle Intelligence Platform**.

The agreed direction is documented in:

- `PROJECT_DIRECTION_CALIBRATION.md`
- `PROJECT_INSTRUCTION.md`
- `README.md`

---

## Current Strategic Direction

The project should build a version-controlled, extensible, evidence-aware, AI-assisted platform for pharmaceutical analytical method lifecycle support.

The platform should support:

1. Product and analytical intent classification
2. Product-type to analytical-method mapping
3. Analytical method development support
4. Method optimization support
5. Validation protocol generation
6. Validation report generation
7. Technical context-aware analytical report review
8. Regulatory / literature / technology intelligence
9. Closed-loop knowledge feedback

---

## Important Architecture Decisions

1. Use **one main repo with multiple modules** at the beginning.
2. Do not split the Technical Context-Aware Analytical Report Review Module into a separate platform.
3. The Technical Context-Aware Analytical Report Review Module is a core child module of the lifecycle platform.
4. GitHub is the source of truth for rules, templates, evidence packs, and version-controlled logic.
5. Notion may be used as dashboard / task tracking, but not as the primary knowledge base.
6. Claude is preferred for final technical reasoning and document drafting.
7. Codex is preferred for repo implementation, schemas, workflows, tests, GitHub Actions, and MCP work.
8. GitHub Actions should be used to refresh and archive official regulatory source metadata.
9. MCP should expose curated evidence packs and repo knowledge to AI clients.
10. All outputs intended for GxP, vendor-facing, or regulatory use require human review.
11. Validation protocol rules are **not SME-approved yet**. They are ready for human review but must not be treated as approved internal guidance until Issue #9 is completed by a qualified reviewer.

---

## Completed Issues

The following issues have been completed:

| Issue | Title | Status | Key Deliverables |
|---:|---|---|---|
| #1 | Expand README into full platform overview | Completed | Platform overview and direction |
| #2 | Expand biologics / recombinant protein DP release and stability method matrix | Completed | Product-type to method matrix MVP |
| #3 | Create synthetic examples and schema validation samples | Completed | Synthetic JSON samples and sample validation workflow |
| #4 | Draft validation protocol generation rules | Completed | Human-readable validation protocol rule set |
| #5 | Build first technical context-aware report review example | Completed | Cell-based potency assay review example, principle card, question bank, gap rules |
| #6 | Implement validation protocol generation engine | Completed | Prototype generator, machine-readable rules, generated JSON and Markdown examples |
| #7 | Add validation protocol rule tests | Completed | Generator tests and GitHub Actions workflow |
| #8 | Create validation protocol markdown generator | Completed | Standalone Markdown renderer, CLI, renderer tests, workflow |
| #10 | Map validation protocol rules to report review gaps | Completed | Protocol-to-gap mapping, machine-readable mapping, feedback workflow |

---

## Open Issues and Human Review Status

Current open issue:

| Issue | Title | Current Status | Required Next Step |
|---:|---|---|---|
| #9 | Review validation protocol rules with SME | **Ready for human review, not completed** | Analytical SME, QA, RA, and/or method owner must review the rule set and document outcome before closure |

Important clarification:

```text
Issue #9 must remain open until a qualified human reviewer completes and documents the review.
```

Prepared review materials for #9:

- `docs/sme_review_package_validation_protocol_rules.md`
- `templates/sme_validation_protocol_rules_review_checklist.md`
- `knowledge_base/reviewer_question_bank/validation_protocol_rules_sme_review_questions.md`

These files prepare the human review package but do **not** complete the human review.

---

## Current Repository Assets

### Core Project Documents

- `README.md`
- `PROJECT_DIRECTION_CALIBRATION.md`
- `PROJECT_INSTRUCTION.md`
- `PROJECT_STATE_CONTINUATION.md`
- `PROJECT_ROADMAP.md`

### Knowledge Base

- `knowledge_base/regulatory_source_priority_matrix.md`
- `knowledge_base/product_type_method_matrix/`
- `knowledge_base/validation_protocol_rules/`
- `knowledge_base/validation_protocol_rules/machine_readable/`
- `knowledge_base/method_principle_cards/`
- `knowledge_base/reviewer_question_bank/`
- `knowledge_base/validation_gap_rules/`
- `knowledge_base/validation_gap_rules/machine_readable/`
- `knowledge_base/analytical_technology_registry/`
- `knowledge_base/evidence_packs/`

### Schemas

- `schemas/product_profile.schema.json`
- `schemas/analytical_method.schema.json`
- `schemas/evidence_source.schema.json`
- `schemas/validation_protocol.schema.json`
- `schemas/technical_context_card.schema.json`
- `schemas/analytical_report_gap_assessment.schema.json`

### Workflows and Templates

- `workflows/product_classification_workflow.md`
- `workflows/method_selection_workflow.md`
- `workflows/validation_protocol_generation_workflow.md`
- `workflows/technical_context_report_review_workflow.md`
- `workflows/protocol_to_report_gap_feedback_workflow.md`
- `templates/validation_protocol_template.md`
- `templates/technical_context_card_template.md`
- `templates/lab_report_gap_assessment_template.md`
- `templates/sme_validation_protocol_rules_review_checklist.md`

### Source Code

- `src/validation_protocol_generator/generate_validation_protocol.py`
- `src/validation_protocol_generator/render_markdown.py`
- `src/validation_protocol_generator/render_validation_protocol_markdown.py`

### GitHub Actions

- `.github/workflows/schema_validation.yml`
- `.github/workflows/sample_schema_validation.yml`
- `.github/workflows/validation_protocol_generator_tests.yml`
- `.github/workflows/markdown_renderer_tests.yml`

### Examples

- `examples/schema_samples/`
- `examples/generated/`
- `examples/technical_context_review/`

### SME Review Package

- `docs/sme_review_package_validation_protocol_rules.md`
- `templates/sme_validation_protocol_rules_review_checklist.md`
- `knowledge_base/reviewer_question_bank/validation_protocol_rules_sme_review_questions.md`

---

## Current Technical Capabilities

The repository currently supports the following draft-only capabilities:

1. Structured product and analytical method profiles.
2. Validation protocol schema and synthetic validation protocol sample.
3. Machine-readable validation characteristic and scope rules.
4. Prototype validation protocol draft JSON generation.
5. Standalone validation protocol Markdown rendering.
6. Synthetic generated protocol examples.
7. Unit tests for generator and Markdown renderer.
8. Technical context-aware report review example for cell-based potency assay.
9. Protocol planning rule to report review gap mapping.
10. SME review package preparation.

All outputs are advisory / draft-only and require human review before real use.

---

## Initial MVP Direction

Initial MVP should prioritize:

```text
biologics / recombinant proteins / drug product release and stability
```

But all schemas, workflows, and knowledge base entries must remain extensible to:

- small molecules
- peptides
- monoclonal antibodies
- ADCs
- oligonucleotides
- vaccines
- cell and gene therapies
- complex formulations

---

## Known Limitations and Required Cautions

1. Validation protocol rules are not yet SME-approved.
2. GitHub Actions run status has not been independently confirmed from the connector in this session.
3. The generator is a first prototype and should be treated as draft-only.
4. Markdown rendering has been added as a standalone renderer; the original generator remains usable and was not force-overwritten after a safety check blocked a broad update.
5. No confidential product, vendor, laboratory, patient, or GxP-controlled information should be committed to examples or tests.
6. Any use for CMC, QA, RA, vendor-facing, GxP, or regulatory purposes requires qualified human review.

---

## Previously Cleaned Issue Noise

The previously accidental issue noise was cleaned up:

- `#11` was closed as not planned.
- `#12`–`#19` were closed.
- `#20` was closed as not planned.
- `#21` was closed as not planned.
- `#22` was closed as not planned.
- `#23` was closed as not planned.
- `#24` was closed as not planned.

Current open issue health check showed only #9 open.

---

## GitHub Actions / CI Health Note

The repository contains schema validation workflows, sample validation workflows, generator tests, and Markdown renderer tests.

During prior health checks, the GitHub connector did not return usable workflow run or status check data for the relevant commits. This means CI status could not be independently confirmed from the connector in this session.

This should be manually checked in the GitHub Actions tab or verified later using an available workflow-run query method.

---

## Recommended Next Work Items

Recommended next sequence:

1. Manually confirm GitHub Actions status for all workflows.
2. Keep #9 open until SME / QA / RA / method owner review is completed and documented.
3. Continue development only with the explicit caveat that validation protocol rules are ready for review but not SME-approved.
4. Candidate next technical work:
   - build a protocol/report review gap extraction prototype using `protocol_to_report_gap_mapping.json`;
   - add tests for the protocol-to-gap mapping file;
   - expand method principle cards beyond cell-based potency assay;
   - add a small user-facing dashboard or CLI index for generated outputs;
   - prepare the first regulatory evidence-pack ingestion prototype.

---

## Direction Calibration Reminder

Before future work, ask:

- Does this support the analytical method lifecycle?
- Does this preserve extensibility beyond recombinant protein MVP?
- Does this separate official evidence from AI inference?
- Does this include human review gates?
- Does this strengthen product-method mapping, method development, validation, report review, regulatory intelligence, or feedback learning?

If not, the work may be outside current project direction.
